Valuation dashboard for Guardant Health, Inc. (GH) with P/E N/A, P/B -105.96, EV/EBITDA -59.9 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI.
Analysis Summary
Guardant Health, Inc. reported revenue of $982.0M in the most recent fiscal year, growing at a 5-year CAGR of 27.9%.
Trailing-twelve-month margins: gross margin 65.0%, operating margin -39.7%, net margin -38.3%.
At $178.80 (closing price, October 30, 2026), GH has negative trailing earnings (P/E not meaningful) and an ROE of 211.46%. Market capitalisation stands at $24.0B, placing it among large-cap names.
Balance sheet quality for GH: debt-to-equity ratio of -7.61, current ratio of 4.03 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -105.96 |
| EV / EBITDA | -59.9 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GH | Guardant Health, Inc. | $24.0B | 211.5% | ||
| NTRA | Natera, Inc. | $59.7B | 32.59 | -11.7% | |
| BLLN | BillionToOne, Inc. | $5.3B | 182.74 | 9.80 | 7.9% |
| GRAL | GRAIL Inc. | $6.4B | 2.43 | -15.9% | |
| NEO | NeoGenomics, Inc. | $2.3B | 2.79 | -4.0% |
Price
| Price | $178.80 (closing price, October 30, 2026) |
| Market Cap | $24.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 211.46% |
| Return on Invested Capital | -29.30% |
| Return on Assets | -23.71% |
| Gross Margin | 65.01% |
| Operating Margin | -39.75% |
| Net Margin | -38.33% |
Related companies: NTRA · BLLN · GRAL · NEO
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of GH: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks